PTO/SB/08a (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known	
Application Number	**10/768,744**
Filing Date	**February 2, 2004**
First Named Inventor	**Christopher A. Hunter**
Group Art Unit	**1647**
Examiner Name	**Cherie Michelle Woodward**
Attorney Docket Number	**120-000220US**
Date Submitted	**March 15, 2010**

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	U.S. Patent Document Number	U.S. Patent Document Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Office	Foreign Patent Document Number	Foreign Patent Document Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	1	Batten et al, (2006) Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. *Nat Immunol* 7:929-936.	
	2	Batten et al, (2007) The biology and therapeutic potential of interleukin 27. *J Mol Med*	
	3	Becker et al, (2005) Stepwise regulation of TH1 responses in autoimmunity: IL-12-related cytokines and their receptors. *Inflamm Bowel Dis* 11:755-764.	
	4	Brombacher et al, (2003) Novel IL-12 family members shed light on the orchestration of Th1 responses. *Trends Immunol* 24:207-212.	
	5	Chen et al, (2000) Development of Th1-type immune responses requires the type I cytokine receptor TCCR. *Nature* 407:916-920.	
	6	Devergne et al, (1996) A novel interleukin-12 p40-related protein induced by latent Epstein-Barr virus infection in B lymphocytes. *Journal Virology* 70:1143-1153.	
	7	Devergne et al, (1997) Epstein-Barr virus-induced gene 3 and the p35 subunit of interleukin 12 form a novel heterodimeric hematopoietin. *Proceedings National Academy Science USA* 94:12041-12046.	
	8	Diveu et al, (2008) Cytokines that regulate autoimmunity. *Curr Opin Immunol* 20:663-668.	
	9	Diveu et al, (2009) IL-27 blocks RORc expression to inhibit lineage commitment of Th17 cells. *J Immunol* 182:5748-5756.	
	10	Fitzgerald et al, (2007) Suppressive effect of IL-27 on encephalitogenic Th17 cells and the effector phase of experimental autoimmune encephalomyelitis. *J Immunol* 179:3268-3275.	
	11	Fitzgerald et al, (2007) Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells. *Nat Immunol* 8:1372-	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/PTO	Complete if Known	
	Application Number	**10/768,744**
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing Date	**February 2, 2004**
	First Named Inventor	**Christopher A. Hunter**
	Group Art Unit	**1647**
(use as many sheets as necessary)	Examiner Name	**Cherie Michelle Woodward**
	Attorney Docket Number	**120-000220US**
	Date Submitted	**March 15, 2010**

		1379.	
	12	Fitzgerald et al, (2009) Therapeutic potential of IL-27 in multiple sclerosis? *Expert Opin Biol Ther* 9:149-160.	
	13	Gabay et al, (2009) The biological and clinical importance of the 'new generation' cytokines in rheumatic diseases. *Arthritis Res Ther* 11:230.	
	14	Goriely et al, (2007) The interleukin-12 family: new players in transplantation immunity? *Am J Transplant* 7:278-284.	
	15	Guo et al, (2008). The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice. *J Clin Invest* 118:1680-1690.	
	16	Hamano et al, (2003) WSX-1 is required for resistance to *Trypanosoma cruzi* infection by regulation of proinflammatory cytokine production. *Immunity* 19:657-667.	
	17	Hibbert et al, (2003) IL-27 and IFN-a signal via Stat1 and Stat3 and induce T-Bet and IL-12Rb2 in naive T cells. *Journal Interferon Cytokine Research* 23:513-522.	
	18	Hunter et al, (2005) New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. *Nat Rev Immunol* 5:521-531.	
	19	Kastelein et al, (2007) Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. *Annu Rev Immunol* 25:221-242.	
	20	Lucas et al, (2003) IL-27 regulates IL-12 responsiveness of naive CD4+ T cells through Stat1-dependent and -independent mechanisms. *Proc Natl Acad Sci U S A* 100:15047-15052.	
	21	Miyazaki et al, (2008) Amelioration of delayed-type hypersensitivity responses by IL-27 administration. *Biochem Biophys Res Commun* 373:397-402.	
	22	Murphy et al, (2002) The lineage decisions of helper T cells. *Nature Reviews Immunology* 2:933-944.	
	23	Niedbala et al, (2008) Interleukin-27 attenuates collagen-induced arthritis. *Ann Rheum Dis.*	
	24	Nieuwenhuis et al, (2002) Disruption of T helper 2-immune responses in Epstein-Barr virus-induced gene 3-deficient mice. *Proceedings National Academy Science USA* 99:16951-11956.	
	25	Pflanz et al, (2002) IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells. *Immunity* 16:779-790.	
	26	Robinson et al, (2002) Further checkpoints in Th1 development. *Immunity* 16:755-758.	
	27	Shimizu et al, (2005) Membranous glomerulonephritis development with Th2-type immune deviations in MRL/lpr mice deficient for IL-27 receptor (WSX-1). *J Immunol* 175:7185-7192.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/PTO	Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	**10/768,744**
	Filing Date	**February 2, 2004**
	First Named Inventor	**Christopher A. Hunter**
	Group Art Unit	**1647**
(use as many sheets as necessary)	Examiner Name	**Cherie Michelle Woodward**
	Attorney Docket Number	**120-000220US**
	Date Submitted	**March 15, 2010**

	28	Sprecher et al, (1998) Cloning and characterization of a novel class I cytokine receptor. *Biochem Biophys Res Commun* 246:82-90.	
	29	Takeda et al, (2003) Cutting edge: Role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment. *Journal Immunology* 170:4886-4890.	
	30	Trinchieri et al, (2003) The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. *Immunity* 19:641-644.	
	31	Vandenbroeck et al, (2004) Inhibiting cytokines of the interleukin-12 family: recent advances and novel challenges. *J Pharm Pharmacol* 56:145-160.	
	32	Villarino et al, (2003) The IL-27R (WSX-1) is required to suppress T cell hyperactivity during infection. *Immunity* 19:645-655.	
	33	Yoshida et al, (2001) WSX-1 is required for the initiation of Th1 responses and resistance to L. major infection. *Immunity* 15:569-578.	
	34	Yoshida et al, (2008) Regulation of immune responses by interleukin-27. *Immunol Rev* 226:234-247.	
	35	Yoshida et al, (2009) Interleukin 27: a double-edged sword for offense and defense. *J Leukoc Biol* 86:1295-1303.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.